Financial Reports
2017 Financial Report
2016 Financial Report
2015 Financial Report
2014 Financial Report
2013 Financial Report
2012 Financial Report
2011 Financial Report
2010 Financial Report
2009 Financial Report
2008 Financial Report
2007 Financial Report
2006 Financial Report
EU Funding
The European Cancer Patient Coalition believes in the value of multidisciplinarity, and recognises the need for informed scientifically correct policy action. Our policy initiatives enjoy the scientific expertise gained through participation in numerous key EU funded projects and built on mutual collaboration of Institutional Partners and active Members.
The European Cancer Patient Coalition is one of the few cancer patient organisation actively involved in the design and implementation of EU funded research projects, among other ongoing activities. The European Cancer Patient Coalition participates in numerous European Union Research and Innovation framework programmes: this includes IMI 1 projects under the Seventh Framework Programme (FP7), and IMI 2 projects under the current Horizon 2020 (H2020).
Industry Funding
It is central to the European Cancer Patient Coalition’s mission to undertake projects that bring significant value to our members and provide meaningful support to Europeans affected by cancer. The European Cancer Patient Coalition is a patient-driven non-profit organisation, very careful about maintaining its independence and making choices based on the needs and perspectives of people affected by cancer. The European Cancer Patient Coalition does not undertake any promotional activity for third parties or take any action that is not in the interest of people with cancer.
The European Cancer Patient Coalition welcomes funding from companies as long as the relationships between the European Cancer Patient Coalition and the commercial companies are based on the following principles:
• Independence: The European Cancer Patient Coalition is the independent voice of Europeans with cancer, devoid of any for-profit activities.
• Transparency: The European Cancer Patient Coalition believes it is important to establish and maintain accountable and transparent relationships with commercial companies in order to enhance communication between Europeans with cancer, whose interests the European Cancer Patient Coalition represents, and the companies, whose decisions will affect the provision of health services.
• Unconditionality: relationships with commercial companies is based on mutual respect while preserving the European Cancer Patient Coalition’s independence and integrity. Any funding from companies must be committed to the benefit of Europeans with cancer, must not entail adverse publicity, and can in no way influence the European Cancer Patient Coalition’s policy, positions or decisions, whether explicitly or implicitly.
• Mutual respect: The European Cancer Patient Coalition views funders as “partners in healthcare” encouraging active partnership between people with cancer and health professionals.
• Sustainability: The European Cancer Patient Coalition expects that funding received allows us to carry out our work and projects, and that it assures the sustainability of our organization.
Expert Groups
All the European Cancer Patient Coalition materials are produced in close partnership with committed researchers, healthcare professionals and other European and national health non-profit organisations. Before embarking on a new topic, the European Cancer Patient Coalition establishes an expert group with the most relevant stakeholders in the field. All materials are produced with input and revision from all members of the group When appropriate, industry funders are members of that group, and as such contribute to the editorial process. The final scope and content are the responsibility of the European Cancer Patient Coalition.
Code of Good Practice
European patient organisations have developed the a transparent and robust Code of Good Practice to guide the relations between patient organisations and the industry (including their representatives and consultants). We encourage all patient organisations to adopt this Code when engaging in a dialogue, working partnership, joint initiative, and/or when accepting support from any funding source. We expect all signatories to adhere to this Code which may be revised over time as circumstances demand. This Code does not intend to cover every possible funding opportunity or relationship, but rather to define a set of basic principles and recommendations.